Ionis Pharmaceuticals (IONS) has provided an update.
Ionis Pharmaceuticals has engaged Onaiza Cadoret-Manier under an advisory services agreement after her departure as an executive to pursue new opportunities. Starting March 15, 2024, Cadoret-Manier will advise the company, earning $12,500 monthly until September 30, and $6,250 thereafter until the agreement concludes on January 10, 2025. Meanwhile, Kyle Jenné rejoins Ionis as executive vice president, tasked with leading the company’s commercialization efforts. Ionis appreciates Cadoret-Manier’s pivotal role in developing its commercial organization during its transition into an integrated biopharmaceutical entity.
See more data about IONS stock on TipRanks’ Stock Analysis page.